These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 12786890)

  • 1. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
    Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
    Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
    Liu YJ; Yan PS; Li J; Jia JF
    World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
    Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
    Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases.
    Sun H; Liu T; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y
    Genes Chromosomes Cancer; 2017 Aug; 56(8):598-607. PubMed ID: 28393427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
    Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
    Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
    Yanagisawa N; Mikami T; Mitomi H; Saegusa M; Koike M; Okayasu I
    Cancer; 2001 Jan; 91(2):408-16. PubMed ID: 11180088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.
    Bànkfalvi A; Terpe HJ; Breukelmann D; Bier B; Rempe D; Pschadka G; Krech R; Böcker W
    Histopathology; 1998 Aug; 33(2):107-16. PubMed ID: 9762542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
    Tran TA; Kallakury BV; Sheehan CE; Ross JS
    Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
    Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
    Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 exon v6 correlates with cellular differentiation but not with progression and metastasis of cervical cancer.
    Tokumo K; Kodama J; Seki N; Miyagi Y; Yoshinouchi M; Kudo T
    Eur J Cancer; 1998 Dec; 34(13):2107-11. PubMed ID: 10070319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of the tumour-associated marker CD44V6 in experimental kidney disease.
    Takazoe K; Foti R; Tesch GH; Hurst LA; Lan HY; Atkins RC; Nikolic-Paterson DJ
    Clin Exp Immunol; 2000 Sep; 121(3):523-32. PubMed ID: 10971520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer.
    Wu XJ; Li XD; Zhang H; Zhang X; Ning ZH; Yin YM; Tian Y
    J Int Med Res; 2015 Apr; 43(2):173-9. PubMed ID: 25571897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of standard and variant CD44 in human lung cancer].
    Zhao H; Fang J; Du G
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep; 21(9):541-3. PubMed ID: 11360506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 variant isoforms in head and neck squamous cell carcinoma progression.
    Wang SJ; Wong G; de Heer AM; Xia W; Bourguignon LY
    Laryngoscope; 2009 Aug; 119(8):1518-30. PubMed ID: 19507218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors.
    Afify AM; Tate S; Durbin-Johnson B; Rocke DM; Konia T
    Int J Biol Markers; 2011; 26(1):50-7. PubMed ID: 21279958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component.
    Umeda T; Ishida M; Murata S; Mori T; Kawai Y; Itoi N; Tomida K; Tanaka A; Sakai S; Kitamura M; Kubota Y; Kushima R; Tani M
    Breast Cancer; 2016 Nov; 23(6):869-875. PubMed ID: 26494575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours.
    Saegusa M; Hashimura M; Machida D; Okayasu I
    J Pathol; 1999 Jan; 187(2):173-83. PubMed ID: 10365092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.